Skip to main content


1. Guarner F et al: Mechanisms of disease: the hygiene hypothesis revisited. Nature Clin Prac 2006, 3,
2. Niess JH , Reinecker HC: Dendritic cells: the commanders-in-chief of mucosal immune defenses. Curr
Opin Gastroenterol 2006, 22, 354-360
3. Shinkai H et al: Biased distributionof single nucleotide polymorphisms (SNPs) in porcine toll-like receptor
1 (TLR-1), TLRs, TLR-4 and TLR-6 genes. Immunogenetics 2006,58,324-330
4. Konstantinos K et al: Circulating levels of leptin, adiponectin, resistin and ghrelin in inflammatory
bowel disese. Inflamm Bowel Dis 2006, 12, 100-105
5. Wehkam J, Stange EF: Paneth cells and the innate immune response. Curr opn Gastroenterol 2006, 22,
6. Van Es JH et al: Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol
2005, 7, 381-386
Egyéb 569
7. Wehkamp J et al: reduced Paneth cell (alpha)-defensins in ileal Crohn’s disease. Proc Netl Acad Sci
USA 2005, 102, 18129-18134
8. Summers RW et al: Trichuris suis therapy in Crohn’s disease. Gut 2005, 54, 87-90
9. Harrington LE et al: Interleukin 17-producing CD4+ effektor T cells develop via a lineage distinct
from the T helper type 1 and 2 lineages. Nat Immunol 2005,6,1123-1132
10. Tato Cm, O’Shea JJ: Immunology: what does it mean to be just 17? Nature 2006,441,461-465
11. Kawashima R et al: IL-13 receptor alpha2 promotes epithelial cell regeneration from radiation-induced
small intestinal injury in mice. Gastroenterology, 2006,131,130-141.
12. Ito H et al: A pilot randomiozed trial of a human anti-interleukin-6 receptor monoclonal antibody in
acttive Crohn’s disease. Gastroenterology, 2004,126,989-996
13. Mannon et al: Anti-12 Crohn’s Disease Study Group. Anti-interleukin-12 antibody for active Crohn’s
disease. N Eng J Med 2004, 351,2069-2079.
14. Sato T et al: Osteopontin/Eta-1 upregulated in Crohn’s disease regulates the Th1 immun response. Gut
15. Heller F et al: Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial
tight junctions, apoptosis, and cell restitution. Gastroenterology, 2005,129,550-564
16. Fichtner-Feigl S et al: IL-13 signaling through the IL-13alpha(2) receptor is involved in induction of
TGF-beta(1) production and fibrosis. Nat Med 2006,12,99-106
17. Kruidenier L et al: Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant
CXCL7 from intestinal epithelial cells. Gastroenterology, 2006,130,127-136
18. Parfitt JR et al: Eosinophilic oesophagitis in adults: distinguishing features from gastroesophageal
reflux disease: a study of 41 patients. Mod Pathol 2006,19,90-96
19. Steiner SJ et al: Severity of basal cell hyperplasia differs in reflux versus eosinophilic esophagitis. J
Pediatr Gastroenterol Nutr 2006,42,506-509
20. Pascal RR et al: Geographic variations in eosinophil concentration in normal colonic mucosa. Mod
Pathol 1997,10,363-365
21. Pensabene L et al: Evaluation of mucosal eosinophils in the pediatric colon. Dig Dis Sci 2005,50,221-229
22. Liacouras CA et al: Eosinophilic esophagitis: a 10 year experience in 381 children. Clin Gastroenterol
Hepatol 2005,3,1198-1208
23. Ngo P et al: Eosinophil granule proteins stimulate intestinal epithelial cell collagen contraction via calciumsensing
receptor activation. Gastroenterology, 2006,130,A89
24. Klion AD et al: The Hypereosinophilic Syndromes Working G: approaches to the treatment of
hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006,117,1292-1302
25. Gupta SK et al: Cytokine expression in normal and inflamed esophageal mucosa: a study into the
pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr, 2006,42,22-26
26. Hogan SP et al: Eosinophil function in eosinophil-associated gastrointestinal disorders. Curr Allergy
Asthma Rep 2006,6,65-71
27. Duncan N et al: Eosinophil-mediated cholinergic nerve remodeling. Am J Respir Cell Mol Biol
28. Chelade M et al: Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology,
clinical course, and long-term follow-up. J Pediatr Gastroenterol Nutr 2006,42,516-521
570 Gastro Update 2008
29. Xanthakos SA et al: Prevalence and outcome of allergic colitis in healthy infants with rectal bleeding:
a prospective cohort study. J Pediatr Gastroenterol Nutr 2005,41,16-22
30. Brandt EB et al: The alpha4beta7-integrin is dynamically expressed on murine eosinophils and
involved in eosinophil trafficking to the intestine. Clin Exp Allergy, 2006,36,543-553
31. Forbes E, et al: ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc
Biol 2006,80,330-341
32. Michail S et al: Role of selectins in the intestinal epithelial migration of eosinophils. Pediatr Res, 2005,
33. Furuta Gt et al: Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J
Physiol Gastrointest Liver Physiol 2005,289,G890-G897
34. Lampinen M et al: Eosinophil granulocytes are activated during the remission phase of ulcerative colitis.
Gut, 2005,54,1714-1720
35. Van der Veek PP et al: Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in
irritable bowel syndrome. Am J Gastroenterol, 2005,100,2510-2516
36. Zar S et al: Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel
syndrome. Am J Gastroenterol, 2005,100,1550-1557
37. Carroccio A et al: Multiple food hypersensitivity as a cause of refractory chronic constipation in adults.
Scand J Gastroenterol 2006,41,498-504
38. Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006,24,147-174
39. Grundy D et al: Fundamentals of neurogastroenterology: basic science. Gastroenterology,
40. Fasano A: Systemic autoimmune disorders in celiac disease. Curr Opin Gastroenterol, 2006,22,674-679
41. Sblattero D et al: Cryptic gluten intolerance in type 1 diabetes: identifying suitable candidates for a
gluten free diet. Gut, 2006,55,133-134
42. Tanure MG et al: Prevalence of celiac disease in Brazilian children with type 1 diabetes mellitus. J Pediatr
Gastroenterol Nutr. 2006,42,155-159
43. Thomas KE et al: Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal
permeability are MyD88-dependent: role of the innate immune response in celiac disease. J Immunol
44. Hold GL et al: A Functional Polymorphism of Toll-like Receptor ! Gene increases Risk of Gastric
Carcinoma and its Precursors. Gastroenterology, 2007, 132, 905-912.
45. Kwok T et al: Helicobacter exploits integrin for type IV secretion and kinase activation. Nature, 2007,
449, 862-867.
46. Tammer I et al: Activation of Abl by Helicobacter pylori: A Novel Kinase for CagA and Crucial Mediator
of Host Cell Scattering. Gastroenterology, 2007, 132, 1309-1319
47. Amedei A et al: The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune
responses. J Clin Invest 2006, 116, 1092-1101.
48. Mcguckin AM et al: Muc1 Mucin Limits Both Helicobacter pylori Colonization of the Murine Gastric
Mucosa and Associated Gastritis. Gastroenterology, 2007, 133, 1210-1218.
49. Barnich N etn al: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa
colonization in Crohn disease. J Clin Invest 2007, 117, 1566-1574.
50. Abraham C, Cho JH: Bugging of the Intestinal Mucosa. N Eng J Med, 2007, 357, 7, 708-710.
Egyéb 571
51. Xavier RJ, Podolsky DK: Unravelling the pathogenesis if inflammatory bowel disease. Nature, 2007,
448, 427-434.
52. Hampe J et al: A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility
variant of Crohn disease in ATG16L1. Natuer Genet 2007, 39, 207-211.
53. Sandborn WJ et al: Certolizumab pegol for ther treatment of Drohn’s disease. N Eng J Med, 2007, 357,
54. Schreiber S et al: Maintenance therapy with certolizumab pegol for Crohn’s disease. N Eng J Med,
2007, 357, 239-250.
55. Schreiber S: Crohn’s disease – infliximab, adalimumab and certolizumab pegol: clinical value of
anti-TNF-alpha treatment. Dtsch Med Wochenschr 2007,132,1770-74.
56. Crispino R et al: Hematological malignancies in chronic inflammatory bowel diseases. Report of five
cases and review of the literature. Int J Colorectal Dis 2007, 22, 553-558.
57. Kapoor S et al: Haemopoietic stem cell transplantation – an evolving treatment for severe autoimmune
and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology,
58. Boirivant M, Strober W: The mechanism of action of probiotics. Curr Opin Gastroenterol 2007,23,679-692.